Case Report

Comparison of Sexual Dysfunction Using the Female Sexual Function Index following Surgical Treatments for Uterine Fibroids

Allison Ryann Louie, Jennifer Alice Armstrong, Laura Katherine Findeiss, and Scott Craig Goodwin

Department of Radiological Sciences, UCI School of Medicine, Irvine, CA 92697, USA

Correspondence should be addressed to Jennifer Alice Armstrong, jenniferarmst@gmail.com

Received 2 June 2012; Accepted 12 July 2012

Academic Editors: S. Z. A. Badawy and E. Cosmi

Copyright © 2012 Allison Ryann Louie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Uterine fibroids are a common problem in women. Statistics showing 20–50% of fibroids produce symptoms and consequently patients seek surgical intervention to improve their quality of life. Treatments for fibroids are typically successful in controlling the fibroid disease, yet sexual function following invasive surgical treatments for fibroids can be jeopardized. The Sexual Function Index (FSFI) is a valid instrument producing quantifiable reproducible results. In this paper three case reports are evaluated by the FSFI and compared between the following treatment groups: hysterectomy, myomectomy, and uterine embolization. Our goal is to illustrate how each of these treatment outcomes can result in sexual dysfunction and therefore decreased quality of life. Effects of invasive fibroid treatments on sexual functioning would be helpful in guiding patient’s ultimate decisions regarding treatment.

1. Introduction

Uterine fibroids are a common problem in the population, many women experience symptoms and some seek surgical intervention to improve their quality of life. Unfortunately, this is not always the outcome. Some patients have a decrease in quality of life due to sexual dysfunction, which is an unexpected adverse event of treatment. Treatments for fibroids are typically successful, yet some women experience an even worse outcome due to adverse effects of the very surgery meant to improve their quality of life. An epidemiologic study published in 2003 found that 80% of African American women and about 70% of Caucasians had evidence of fibroids on ultrasound [1]. In this population, it is estimated that 20–50% of fibroids produce symptoms including menorrhagia, dysmenorrhea, pelvic pain and pressure, dyspareunia, and/or urinary frequency and urgency [2]. Severe symptomatic fibroids warrant surgical treatment, the standard being a hysterectomy or in patients desiring fertility myomectomy.

There is controversy in the medical literature regarding quality of life with regard to sexual function following surgical treatments for fibroid disease [3–6]. The controversy lies in the subjectivity of the topic, making it difficult to assess the baseline prevalence of sexual dysfunction in women with fibroids [7, 8]. To overcome this challenge the Female Sexual Function Index (FSFI) was established [9, 10]. This test has been established as a valid instrument producing quantifiable reproducible results. In this study, patient’s sexual function, evaluated by the FSFI and compared between the following treatment groups: hysterectomy, myomectomy, and uterine embolization. Our goal is to illustrate how each of these treatment outcomes affect sexual dysfunction and therefore quality of life.

2. Female Sexual Function

There are different theories regarding female sexual function. According to Masters and Johnson, the female sexual response consists of four successive stages: excitement,
plateau, orgasmic, and resolution phases [11]. Kaplan proposed the aspect of “desire” and condensed the cycle into just three phases, removing the aspect of resolution [12]. The Kaplan model is widely accepted today but might not fully take into account nonbiologic factors and relationship context [13–15].

2.1. Anatomy and Physiology of Female Sexual Function. The pelvic autonomic nerves supply the blood vessels of the vaginal wall, which originate mostly from the inferior hypogastric plexus (IHP). The IHP is essential for lubrication and sensation of the internal genitalia [16, 17]. The sensation of the external genitalia is linked to the pudendal nerve; this somatosensory nerve supplies the labia and clitoris, and reaches the external genitalia through a canal within the pelvic floor [18]. A number of studies related to hysterectomy and female sexual functioning have led researchers to conclude that disruption of the autonomic nerve supply leads to specific sexual disturbances. Disruption of the sympathetic nerve supply will lead to impaired lubrication and altered sensation of the female internal genital organs, and damage to the parasympathetic nerve supply will lead to impairment of vasocongestion [19, 20].

The hormonal milieu also plays an important role in female sexual functioning. Estrogen levels are related to the health of the vaginal wall and to lubrication, while androgens play an important role in sexual desire [21–24].

According to some research, there are two different types of female orgasm: internal and external. Some women describe the internal orgasm to occur when the pressure of the penis presses against the cervix. It has been suggested that the removal of the cervix can eliminate internal orgasm [25]. The external orgasm involves the clitoris, which is believed to produce sexual enjoyment for the majority of women [24]. External orgasm capability is reliant on the pudendal nerve, it supplies sensation to the external genitalia, that is, the labia and the clitoris [16]. The pudendal nerve can be compromised in hysterectomy and contribute to sexual dysfunction.

3. Sexual Dysfunction following Invasive Therapy for Uterine Fibroid Disease

3.1. Hysterectomy

3.1.1. Case Report. The patient was a 52-year-old G1P1 female. She had menorrhagia secondary to five intracavitary submucosal fibroids. She also had a complex ovarian cyst on the right. She underwent a total abdominal hysterectomy and a right salpingo oophorectomy. She experienced postsurgical menopause after the hysterectomy associated with low testosterone levels. She experienced decreased sexual desire and difficulty in experiencing orgasm. She was treated with testosterone cream (Andro-Feme (Lawley Pharmaceuticals, Perth, Australia)) and tibolone (Naari AG, Oberwil, Switzerland) which was then changed to an estradiol patch (Estrados, Novartis International AG, Basel, Switzerland). The FSFI questionnaire was administered. She reported scores for three time points. These included the time at which her sexual function was at its: (1) best prior to surgery-(32.2); (2) worst after surgery-(9.6); (3) best after hormonal therapy (17.5). Her scores are shown in Table 1.

The results following hysterectomy can be both negative and positive. Positive outcomes include cessation of abnormal uterine bleeding, reduction in pelvic pain, and a decrease in depression and anxiety [26]. Generally, women display satisfaction with this procedure because their predisposing condition(s) are ultimately removed [27]. However, studies have shown that a significant proportion of women will develop new symptoms after hysterectomy, which include depression, fatigue, urinary incontinence, constipation, early ovarian failure, and sexual dysfunction [28, 29]. Many concerns have been raised regarding the appropriateness of this procedure for benign conditions, especially since it has an overall complication rate of 17–23% [30].

3.1.2. Sexual Dysfunction Associated with Hysterectomy. The literature regarding sexual outcomes after hysterectomy is often conflicting and there remains debate as to what symptoms will be alleviated or improved after hysterectomy [5, 28, 31–33]. Some studies report that many women will experience sexual improvement due to the extirpation of a diseased uterus [5, 28, 29, 34] and that sexual desire and orgasm are likely to remain the same or become enhanced following surgery [35, 36]. Other investigators have estimated anywhere between 4% [37] and 40% [38] of women will report decreases in sexual desire after hysterectomy and an estimated 8% [39] to 25% [40] of women will experience decreased orgasmic ability.

The performance of a hysterectomy places a patient at risk of damage to the pelvic plexus [17]. With a more radical the surgery, the patient has a greater risk of nerve damage. Radical hysterectomy for cervical cancer causes greater nerve damage because the procedure involves the removal of the uterus and cervix as well as its lateral anterior and posterior
ligaments [17]. These ligaments serve as pathways for the pelvic autonomic nerves; therefore, disruption of these nerves seems unavoidable during radical hysterectomy [17]. However, in 2003 new techniques were developed in radical hysterectomy to help identify and preserve the autonomic nerves, in hopes of preventing postoperative bowel, bladder, and sexual dysfunction [5, 41].

In relation to the cervix and sexual dysfunction, one hypothesis claims that removing the cervix can cause shortening and narrowing of the vaginal vault, which can result in severe dyspareunia and altered sensations during coitus. Formation of scar tissue in the vaginal cuff can also be a reason for dyspareunia [42]. It has also been suggested that the removal of the cervix can eliminate the experience of an internal orgasm [23].

Women who undergo oophorectomy experience a marked decrease in certain hormones which can cause symptoms that are typically seen in postmenopausal women, including sexual dysfunction. Oophorectomy patients experience a physiological decrease in estrogen and androgen levels, which results in reduced vaginal lubrication and dyspareunia [18]. An androgen deficiency is believed to be a cause of reduced libido and reduced sexual arousability [18–21].

The contributing factors that lead up to sexual dysfunction are multivariate. Although many investigators report hysterectomy does alter, to some proportion, the physiology of the female sexual response, there are still many researchers and studies that say otherwise. Moreover, the literature that addresses the costs and benefits of hysterectomy primarily focuses on overall efficacy and safety rather than on the patients who have particular adverse events such as sexual dysfunction.

3.2. Myomectomy

3.2.1. Case Report. The patient was a 39-year-old G0P0 who underwent a myomectomy for the removal of 13 fibroids. Prior to myomectomy, she had dysmenorrhea, menorrhagia, dyspareunia, and bulk symptoms. Her postoperative course was complicated by an infection, yet 8 weeks post-op her symptoms were much improved. After four months, her dyspareunia returned and she was found to have three small fibroids. Four months later, she underwent laparoscopic surgery that revealed multiple adhesions. The adhesions were removed and the patients dyspareunia resolved post-op. The FSFI questionnaire was administered. She reported scores for five time points. These included the time at which her sexual function was at its: (1) best prior to surgery (33); (2) worst just prior to surgery (20); (3) best after first surgery (32.2); (4) worst after first surgery (24.9); (5) after second surgery (32.6). Her detailed scores are shown in Table 2.

Myomectomy is an invasive surgical procedure that removes fibroids and conserves the uterus; therefore, it has become the standard procedure for patients who wish to preserve fertility [43]. It can be performed hysteroscopically, laparoscopically, or via laparotomy, depending on the size, location, and number of fibroids, and the experience of the surgeon [44].

3.2.2. Sexual Dysfunction Associated with Myomectomy. A literature review did not reveal any adverse effects of sexual dysfunction following myomectomy, with the exception of those related to adhesions, which are common in any abdominal surgical procedure [46]. Approximately 40% of chronic pelvic pain cases are directly related to adhesions [46, 47]. Pain from adhesions is probably related to their effect on adjacent structures. For example, it is known that adhesions around the ovaries can be associated with pain probably secondary to obstruction of the tubes and traction on the ovary [48, 49].

More studies are needed in order to investigate the relationship is between postmyomectomy adhesions and sexual functioning. Although assurance of a successful medical outcome is important, patients’ postoperative quality of life is also essential.

3.3. UAE

3.3.1. Case Report. The patient was a 40-year-old G4P3SAB1. On ultrasound she had a 20 cm uterus. Her symptoms included dysmenorrhea and menorrhagia. She underwent uterine artery embolization (UAE) and her symptoms improved. The FSFI was administered for three time points. These included the time at which her sexual function was at its: (1) best prior to UAE (34.5); (2) worst after UAE (19.8); (3) best after hormonal therapy (34.5). Her detailed scores are shown in Table 3.

A successful UAE procedure results in the resolution of presenting symptoms, such as menorrhagia, pain, urinary frequency, or constipation, without additional therapy [50]. UAE provides many benefits such as preservation of the uterus, avoidance of general anesthesia, a lower complications rate, and a substantially shorter recovery period [51].
UAE and fertility are currently under investigation and therefore not recommended for women who are trying to conceive [51].

Fibroid recurrence with UAE is thought to be 5% per year and is largely attributed to incompletely infarcted fibroids [52–54]. Overall, UAE has been reported to be an effective minimally invasive therapeutic alternative with high patient satisfaction rates [55–58].

3.3.2. Sexual Dysfunction Associated with UAE. UAE has rarely been shown to have sexual complications. When it does occur, it is due to unintended embolization of the cervicovaginal branches of the uterine artery, which may lead to impairment in achieving orgasm and lubrication [6, 59]. Yet, many studies have displayed positive results concerning sexual functioning after UAE. A minority of patients report sexual dysfunction compared to other fibroid treatments. For the welfare of future UAE patients, Lai et al. have suggested that objective questionnaires, complex hormonal evaluations, and complete sexual histories be completed to evaluate and stratify the risk of sexual dysfunction following UAE [59].

4. Conclusion

The postoperative sexual function and subsequent quality of life is an important part of a successful procedure. Unfortunately, the topic of sexual function is insufficiently discussed in the literature.

Patients undergo procedures with the expectations to alleviate symptoms and improve their quality of life. The expectations of the outcome should be discussed along with the risks and benefits of each procedure.

For the welfare of future hysterectomy, myomectomy, and UAE patients, additional attention should be paid to sexual function. Clinicians have proposed that in addition to the patient and physician discussion, there should be objective questionnaires and hormonal evaluations [59].

These case reports and the literature illustrate the possibility of sexual dysfunction after invasive fibroid procedures for fibroid disease. Further studies on the effects of invasive fibroid treatments on sexual functioning would be helpful in guiding patient’s ultimate decisions regarding treatment.

**Table 3: UAE patient FSFI.**

| Domain          | Score time point | 1 | 2 | 3 |
|-----------------|------------------|---|---|---|
| Desire          | 4.8              | 6.0| 6.0| |
| Arousal         | 5.7              | 1.2| 5.7| |
| Lubrication     | 6.0              | 4.2| 6.0| |
| Orgasm          | 6.0              | 1.2| 4.8| |
| Satisfaction    | 6.0              | 1.2| 6.0| |
| Pain            | 6.0              | 6.0| 6.0| |
| Full scale score| 34.5             | 19.8| 34.5| |

**Summary**

Sexual dysfunction can occur after the invasive treatment of uterine fibroids. This is an adverse effect that is relatively understudied and can have a profound effect on patients’ quality of life.

**References**

[1] D. D. Baird, D. B. Dunson, M. C. Hill, D. Cousins, and J. M. Schectman, “High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence,” *American Journal of Obstetrics and Gynecology*, vol. 188, no. 1, pp. 100–107, 2003.

[2] S. Gupta, J. Jose, and I. Manyonda, “Clinical presentation of fibroids,” *Best Practice and Research*, vol. 22, no. 4, pp. 615–626, 2008.

[3] S. Ferrero, L. H. Abbamonte, M. Giordano, M. Parisi, N. Ragni, and V. Remorgida, “Uterine myomas, dyspareunia, and sexual function,” *Fertility and Sterility*, vol. 86, no. 5, pp. 1504–1510, 2006.

[4] D. Ertunc, R. Uzun, E. C. Tok, A. Doruk, and S. Dilek, “The effect of myoma uteri and myomectomy on sexual function,” *Journal of Sexual Medicine*, vol. 6, no. 4, pp. 1032–1038, 2009.

[5] J. C. Rhodes, K. H. Kjerulf, P. W. Langenberg, and G. M. Guzinski, “Hysterectomy and sexual functioning,” *Journal of the American Medical Association*, vol. 282, no. 20, pp. 1934–1941, 1999.

[6] M. J. Voogt, J. De Vries, W. Fonteijn, P. N. M. Lohle, and P. F. Boekkooi, “Sexual functioning and psychological well-being after uterine artery embolization in women with symptomatic uterine fibroids,” *Fertility and Sterility*, vol. 92, no. 2, pp. 756–761, 2009.

[7] S. A. Lippman, M. Warner, S. Samuels, D. Olive, P. Vercellini, and B. Eskenazi, “Uterine fibroids and gynecologic pain symptoms in a population-based study,” *Fertility and Sterility*, vol. 80, no. 6, pp. 1488–1494, 2003.

[8] G. Pron, M. Cohen, J. Soucie, G. Garvin, L. Vanderburgh, and S. Bell, “The Ontario Uterine Fibroid Embolization Trial. Part I. Baseline patient characteristics, fibroid burden, and impact on life,” *Fertility and Sterility*, vol. 79, no. 1, pp. 112–119, 2003.

[9] R. Rosen, C. Brown, J. Heiman et al., “The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function,” *Journal of Sex and Marital Therapy*, vol. 26, no. 2, pp. 191–208, 2000.

[10] M. Wiegel, C. Meston, and R. Rosen, “The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores,” *Journal of Sex and Marital Therapy*, vol. 31, no. 1, pp. 1–20, 2005.

[11] W. H. Masters and V. E. Johnson, *Reproductive Biology Research Foundation (U.S.). Human Sexual Response*, Little, Brown, Boston, Mass, USA, 1st edition, 1966.

[12] H. S. Kaplan, *The New Sex Therapy; Active Treatment of Sexual Dysfunctions*, Brunner/Mazel, New York, NY, USA, 1974.

[13] J. R. Berman, “Physiology of female sexual function and dysfunction,” *International Journal of Impotence Research*, vol. 17, no. 1, pp. S44–S51, 2005.

[14] L. Tiefer, L. Alperstein, C. Ellison et al., “A new view of women’s sexual problems,” *Electronic Journal of Human Sexuality*, vol. 3, 2000.

[15] M. L. Sipksi and C. J. Alexander, *Sexual Function in People with Disability and Chronic Illness: A Health Professional’s Guide*, Aspen Publishers, Gaithersburg, Md, USA, 1997.
A. Schwenkhagen and J. Studd, “Role of testosterone in the...”

L. A. Lepine, S. D. Hillis, P. A. Marchbanks et al., “Hysterectomy...”

R. Thakar, S. Ayers, P. Clarkson, S. Stanton, and I. Manyonda, “Pelvic nerve plexus trauma at radical and simple hysterectomy: a quantitative study of nerve types in the uterine supporting ligaments,” Journal of the Society for Gynecologic Investigation, vol. 9, no. 1, pp. 47–56, 2002.

N. L. McCoy, “Longitudinal study of menopause and sexuality,” Acta Obstetricia et Gynecologica Scandinavica, vol. 81, no. 7, pp. 617–622, 2002.

S. B. Bellerose and Y. M. Binik, “Body image and sexuality in oophorectomized women,” Archives of Sexual Behavior, vol. 22, no. 5, pp. 435–459, 1993.

A. Schwenkhagen and J. Studd, “Role of testosterone in the treatment of hypoactive sexual desire disorder,” Maturitas, vol. 63, no. 2, pp. 152–159, 2009.

R. E. Nappi and P. Polatti, “The use of estrogen therapy in women’s sexual functioning (CME),” Journal of Sexual Medicine, vol. 6, no. 3, pp. 603–616, 2009.

R. Basson, “Human sex-response cycles,” Journal of Sex and Marital Therapy, vol. 27, no. 1, pp. 33–43, 2001.

H. M. Hasson, “Cervical removal at hysterectomy for benign disease: risks and benefits,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 38, no. 10, pp. 781–790, 1993.

C. M. Farquhar, S. A. Harvey, Y. Yu, L. Sadler, and A. W. Stewart, “A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy,” American Journal of Obstetrics and Gynecology, vol. 194, no. 3, pp. 711–717, 2006.

R. Thakar, S. Ayers, A. Georgakapolou, P. Clarkson, S. Stanton, and I. Manyonda, “Hysterectomy improves quality of life and decreases psychiatric symptoms: a prospective and randomised comparison of total versus subtotal hysterectomy,” British Journal of Obstetrics and Gynaecology, vol. 111, no. 10, pp. 1115–1120, 2004.

K. J. Carlson, B. A. Miller, and F. J. Fowler, “The Maine Women’s Health Study: I. Outcomes of hysterectomy,” Obstetrics and Gynecology, vol. 83, no. 4, pp. 556–565, 1994.

K. H. Kjerulf, P. W. Langenberg, J. C. Rhodes, L. A. Harvey, G. M. Guzinski, and P. D. Stolley, “Effectiveness of hysterectomy,” Obstetrics and Gynecology, vol. 95, no. 3, pp. 319–326, 2000.

J. Mäkinen, J. Johansson, C. Tomás et al., “Morbidity of 10 110 hysterectomies by type of approach,” Human Reproduction, vol. 16, no. 7, pp. 1473–1478, 2001.

L. A. Lepine, S. D. Hillis, P. A. Marchbanks et al., “Hysterectomy Surveillance—United States, 1980–1993,” Morbidity and Mortality Weekly Report, vol. 46, no. 4, pp. 1–15, 1997.

R. Thakar, S. Ayers, P. Clarkson, S. Stanton, and I. Manyonda, “Outcomes after total versus subtotal abdominal hysterectomy,” New England Journal of Medicine, vol. 347, no. 17, pp. 1318–1325, 2002.

A. M. Weber, M. D. Walters, L. R. Schover, J. M. Church, and M. R. Piedmonte, “Functional outcomes and satisfaction after abdominal hysterectomy,” American Journal of Obstetrics and Gynecology, vol. 181, no. 3, pp. 530–535, 1999.

I. Ceausu, Y. A. Shakir, J. Lidfeldt, G. Samsioe, and C. Nervbrand, “The hysterectomized woman: is she special? The women’s health in the Lund area (WHILA) study,” Maturitas, vol. 53, no. 2, pp. 201–209, 2006.

L. Dennerstein, C. Wood, and G. D. Burrows, “Sexual response following hysterectomy and oophorectomy,” Obstetrics and Gynecology, vol. 49, no. 1, pp. 92–96, 1977.

A. Coppen, M. Bishop, and R. J. Beard, “Hysterectomy, hormones, and behaviour. A prospective study,” The Lancet, vol. 1, no. 8212, pp. 126–128, 1981.

C. P. Maas, F. T. M. Weijenberg, and M. M. Ter Kuile, “The effect of hysterectomy on sexual functioning,” Annual Review of Sex Research, vol. 14, pp. 83–113, 2003.

M. J. Schofield, A. Bennett, S. Redman, W. A. W. Walters, and R. W. Sanson-Fisher, “Self-reported long-term outcomes of hysterectomy,” British Journal of Obstetrics and Gynaecology, vol. 98, no. 11, pp. 1129–1136, 1991.

S. Carranza-Lira, A. Murillo-Uribe, N. M. Trejo, and J. Santos-González, “Changes in symptomatology, hormones, lipids, and bone density after hysterectomy,” International Journal of Fertility and Women’s Medicine, vol. 42, no. 1, pp. 43–47, 1997.

W. Eicher, “Total and subtotal hysterectomy—psychosexual aspects,” Archives of Gynecology and Obstetrics, vol. 255, supplement 2, pp. 359–366, 1994.

M. F. Goetsch, “The effect of total hysterectomy on specific sexual sensations,” American Journal of Obstetrics and Gynecology, vol. 192, no. 6, pp. 1922–1927, 2005.

P. Kilkku, M. Gronroos, T. Hirvonen, and L. Rauramo, “Supravaginal uterine amputation versus hysterectomy. Effects on libido and orgasm,” Acta Obstetricia et Gynecologica Scandinavica, vol. 62, no. 2, pp. 147–152, 1983.

A. Khaund and M. A. Lumsden, “Impact of fibroids on reproductive function,” Best Practice and Research, vol. 22, no. 4, pp. 749–760, 2008.

A. A. Luciano, “Myomectomy,” Clinical Obstetrics and Gynecology, vol. 52, no. 3, pp. 362–371, 2009.

M. Mara, J. Maskova, Z. Fucikova, D. Kuzel, T. Belsan, and O. Sosna, “Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy,” CardioVascular and Interventional Radiology, vol. 31, no. 1, pp. 73–85, 2008.

W. H. Parker, “Laparoscopic myomectomy and abdominal myomectomy,” Clinical Obstetrics and Gynecology, vol. 49, no. 4, pp. 789–797, 2006.

Polish Gynecological Society, “Polish gynecological society consensus in adhesion reduction management,” Ginekologia Polska, vol. 81, no. 3, pp. 235–236, 2010.

F. M. Howard, “The role of laparoscopy in chronic pelvic pain: promise and pitfalls,” Obstetrical and Gynecological Survey, vol. 48, no. 6, pp. 357–387, 1993.

D. M. Duffy and G. S. DiZerega, “Adhesion controversies: pelvic pain as a cause of adhesions, crystalloids in preventing them,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 41, no. 1, pp. 19–26, 1996.

D. M. Hovsepian, G. P. Siskin, J. Bonn et al., “Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata,” Journal of Vascular and Interventional Radiology, vol. 15, no. 6, pp. 535–541, 2004.

L. D. Bradley, “Uterine fibroid embolization: a viable alternative to hysterectomy,” American Journal of Obstetrics and Gynecology, vol. 201, no. 2, pp. 127–135, 2009.

J. B. Spies, S. A. Ascher, A. R. Roth, J. Kim, E. B. Levy, and J. Gomez-Jorge, “Uterine artery embolization for leiomyomata,” Obstetrics and Gynecology, vol. 98, no. 1, pp. 29–34, 2001.
[53] J. P. Pelage, N. G. Guou, R. C. Jha, S. M. Ascher, and J. B. Spies, “Uterine fibroid tumors: long-term MR imaging outcome after embolization,” Radiology, vol. 230, no. 3, pp. 803–809, 2004.

[54] S. Yousefi, F. Czeyda-Pommersheim, A. M. White, F. Banovac, W. Y. Hahn, and J. B. Spies, “Repeat uterine artery embolization: indications and technical findings,” Journal of Vascular and Interventional Radiology, vol. 17, no. 12, pp. 1923–1929, 2006.

[55] S. C. Goodwin, J. B. Spies, R. Worthington-Kirsch et al., “Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID registry,” Obstetrics and Gynecology, vol. 111, no. 1, pp. 22–33, 2008.

[56] J. G. Moss, K. G. Cooper, A. Khaund et al., “Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-Year results,” British Journal of Obstetrics and Gynaecology, vol. 118, no. 8, pp. 936–944, 2011.

[57] S. M. Van Der Kooij, W. J. K. Hehenkamp, N. A. Volkers, E. Birnie, W. M. Ankum, and J. A. Reekers, “Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-Year outcome from the randomized EMMY trial,” American Journal of Obstetrics and Gynecology, vol. 203, no. 2, pp. 105.e101–105.e115, 2010.

[58] A. Hirst, S. Dutton, O. Wu et al., “A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study,” Health Technology Assessment, vol. 12, no. 5, pp. 1–248, 2008.

[59] A. C. Lai, S. C. Goodwin, S. M. Bonilla et al., “Sexual dysfunction after uterine artery embolization,” Journal of Vascular and Interventional Radiology, vol. 11, no. 6, pp. 755–758, 2000.